Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals Announces Appointment of Daniel W. Olmstead as Vice President, Payer Access

DGAP-News: Keryx Biopharmaceuticals, Inc. /

21.01.2014 / 14:30

---------------------------------------------------------------------

Formerly Senior Director, Corporate Accounts at Genzyme/Sanofi Renal

NEW YORK, 2014-01-21 14:30 CET (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals,
Inc. (Nasdaq:KERX), a biopharmaceutical company focused on the acquisition,
development and commercialization of medically important pharmaceutical
products for the treatment of renal disease (the 'Company'), today announced
the appointment of Daniel W. Olmstead to the newly created position of Vice
President, Payer Access. In this role, Mr. Olmstead will lead the Company's
strategic global market access, managed care and reimbursement initiatives. 

Mr. Olmstead brings more than 25 years of healthcare experience, with the
majority of this time spent in a variety of managed market roles, including
reimbursement access, contracting, and product launch planning and execution.
Prior to joining the Company, Mr. Olmstead was a National Account Director for
Walgreen Co. (NYSE:WAG), where he represented all Walgreens business units with
Express Scripts, its largest volume retail client. Prior to joining Walgreens
in 2012, Mr. Olmstead spent more than 7 years with Genzyme/Sanofi, ultimately
rising to Senior Director, Corporate Accounts. During his tenure at
Genzyme/Sanofi, Mr. Olmstead served in roles of increasing responsibility
within the Renal Division, including coverage of key national and regional
health plans, managed markets product launch planning, and playing an integral
role in establishing Renal pricing and contracting strategies for
Renagel(R)/Renvela(R), Hectorol(R) and other products. Mr. Olmstead received his
Bachelor's degree from the University of Michigan, Ann Arbor. 

Daniel P. Regan, a member of Keryx's Board of Directors, and formerly Global
General Manager, Senior Vice President of the Renal Franchise at
Genzyme/Sanofi, commented, 'Having worked with Dan at Genzyme/Sanofi for
several years, I believe that he will be a tremendous asset to the Company at
this critical juncture. Dan is a consummate professional and I believe that his
breadth of experience, particularly in the Renal space, will help the Company
develop and implement sound pricing, market access and reimbursement approaches
globally to achieve commercial success.' 

Ron Bentsur, Keryx's Chief Executive Officer, said, 'We are excited to welcome
Dan to the Company and we look forward to leveraging his expertise as we
prepare for the potential launch of Zerenex.' 

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and
commercialization of medically important pharmaceutical products for the
treatment of renal disease. Keryx is developing Zerenex(TM) (ferric citrate
coordination complex), an oral, ferric iron-based compound. Keryx has completed
a U.S.-based Phase 3 clinical program for Zerenex for the treatment of
hyperphosphatemia (elevated phosphate levels) in patients with chronic kidney
disease (CKD) on dialysis, conducted pursuant to a Special Protocol Assessment
(SPA) agreement with the Food and Drug Administration (FDA). The Company's New
Drug Application (NDA) is currently under review by the FDA with an assigned
Prescription Drug User Fee Act (PDUFA) goal date of June 7, 2014. The Marketing
Authorization Application (MAA) filing with the European Medicines Agency (EMA)
is pending. The Company is also developing Zerenex in the U.S. for the
treatment of iron deficiency anemia and management of elevated phosphorus in
patients with Stage 3 to 5 non-dialysis dependent CKD. 

In addition, Keryx's Japanese partner, Japan Tobacco Inc. (JT) and Torii
Pharmaceutical Co., Ltd. (Torii), has received manufacturing and marketing
approval of ferric citrate from the Japanese Ministry of Health, Labour and
Welfare. Ferric citrate, to be marketed in Japan by JT's subsidiary, Torii,
under the brand name Riona(R), is indicated as an oral treatment for the
improvement of hyperphosphatemia in patients with CKD, including dialysis and
non-dialysis dependent CKD. 

Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those
relating to the commercial opportunity, competitive positioning, and business
prospects for Zerenex, may be forward-looking statements that involve a number
of risks and uncertainties. For those statements, we claim the protection of
the safe harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995. Among the factors that could cause
our actual results to differ materially are the following: acceptance of the
NDA filing represents only a preliminary evaluation of the application and is
not indicative of deficiencies that may be identified during the FDA's review;
a PDUFA goal date is subject to change and does not guarantee that the review
of the NDA will be completed on a timely basis; the risk that the FDA and/or
EMA ultimately deny approval of the U.S. NDA and/or MAA, respectively; the risk
that SPAs are not a guarantee that the FDA will ultimately approve a product
candidate following filing acceptance; whether the FDA and EMA will concur with
our interpretation of our Phase 3 study results, supportive data, or the
conduct of the studies; whether, Zerenex, if approved, will be successfully
launched and marketed; and other risk factors identified from time to time in
our reports filed with the Securities and Exchange Commission. Any
forward-looking statements set forth in this press release speak only as of the
date of this press release. We do not undertake to update any of these
forward-looking statements to reflect events or circumstances that occur after
the date hereof. This press release and prior releases are available at
http://www.keryx.com. The information found on our website is not incorporated
by reference into this press release and is included for reference purposes
only. 


         KERYX CONTACT:
         Lauren Fischer
         Director - Investor Relations
         Keryx Biopharmaceuticals, Inc.
         Tel: 212.531.5965
         E-mail: lfischer@keryx.com
News Source: NASDAQ OMX


End of Corporate News

---------------------------------------------------------------------

21.01.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English                         
Company:     Keryx Biopharmaceuticals, Inc.  
 
 
             United States                   
ISIN:        US4925151015                    
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
248916 21.01.2014